阿尼鲁单抗在系统性红斑狼疮患者中最佳给药方案的暴露-反应分析
基于随机双盲2b期MUSE研究,采用群体方法分析阿尼鲁单抗(300 mg或1000 mg每4周一次)在慢性中重度SLE患者中的暴露-反应关系、药代动力学和SRI(4)疗效数据。模型显示I型IFNGS高患者和体重较高者药物清除率显著更高,模拟提示低于300 mg的剂量因抗原 sink 效应导致暴露非比例下降和SRI(4)应答欠佳。基于PK、疗效和安全性考虑,推荐阿尼鲁单抗300 mg每4周一次作为SLE关键3期研究的最佳剂量。
要点
- I型IFNGS高和体重较高的SLE患者阿尼鲁单抗清除率显著更高。
- 低于300 mg的剂量因抗原 sink 效应导致暴露非比例下降和SRI(4)应答欠佳。
- 推荐阿尼鲁单抗300 mg每4周一次作为SLE关键3期研究的最佳剂量。
核心结论
- 基于PK、疗效和安全性考虑,推荐阿尼鲁单抗300 mg每4周一次作为SLE关键3期研究的最佳剂量。
研究设计与样本
- 基于随机双盲2b期MUSE研究,采用群体方法分析阿尼鲁单抗的暴露-反应关系、药代动力学和SRI(4)疗效数据,并纳入脱落风险函数描述1年治疗期间的自愿退出。
主要发现
- 群体PK模型发现I型IFNGS高患者和体重较高的患者阿尼鲁单抗清除率显著更高。
- 随机临床模拟显示低于300 mg的剂量因I型IFNα受体介导的药物清除(抗原 sink 效应,低浓度下清除更快)导致药物暴露非比例下降和SRI(4)应答欠佳且置信区间更宽。
临床怎么用
- 在SLE关键3期研究中推荐采用阿尼鲁单抗300 mg每4周一次作为最佳剂量方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The randomized, double-blind, phase 2 b MUSE study evaluated the efficacy and safety of the type I IFN receptor antibody anifrolumab (300 mg or 1000 mg every 4 weeks) compared with placebo for 52 weeks in patients with chronic, moderate to severe SLE. Characterizing the exposure-response relationship of anifrolumab in MUSE will enable selection of its optimal dosage regimen in two phase 3 studies in patients with SLE. METHODS: The exposure-response relationship, pharmacokinetics (PK) and SLE Responder Index (SRI(4)) efficacy data were analysed using a population approach. A dropout hazard function was also incorporated into the SRI(4) model to describe the voluntary patient withdrawals during the 1-year treatment period. RESULTS: The population PK model found that type I IFNGS-high patients, and patients with a higher body weight, had significantly greater clearance of anifrolumab. Stochastic clinical simulations demonstrated that doses <300 mg would lead to a greater-than-proportional reduction in drug exposure owing to type I IFN alpha receptor-mediated drug clearance (antigen-sink effect, more rapid drug clearance at lower concentrations) and suboptimal SRI(4) responses with wider confidence intervals. CONCLUSIONS: Based on PK, efficacy and safety considerations, anifrolumab 300 mg every 4 weeks was recommended as the optimal dosage for pivotal phase 3 studies in patients with SLE.
引用
- Chia YL, Santiago L, Wang B, et al. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2021. PMID: 33629110. doi:10.1093/rheumatology/keab176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。